Dimopoulos MA, Dytfeld D, Grosicki S, et al. Elotuzumab plus pomalidomide/dexamethasone (EPd) vs Pd for treatment of relapsed/refractory multiple myeloma (RRMM): results from the phase 2, randomized open-label ELOQUENT-3 study, EHA 2018, abstract LB2606.
Relatie tussen reduced intensity conditioneringsregimes en overleving bij NHL-patiënten
sep 2020 | Lymfoom, Stamceltransplantatie